ArticleCancer discovery2017
Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 574 papers.
0numbers the graph read from it
0cells of the map it votes in
574citing papers in PubMed
40.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
574 citing papers in PubMed, 895 citations in OpenAlex.
- Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study.Molecular cancer · 2025Trial
- Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.Cancer research · 2025Trial
- Inhibition of PHB2/PINK1-mediated mitophagy potentiates venetoclax activity in acute myeloid leukemia.Leukemia · 2026Article
- A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist.HemaSphere · 2026Article
- A novel combination approach targeting P300 and DNA-PK exploits epigenetic dependencies in acute myeloid leukemia.Molecular therapy. Oncology · 2026Article
- Non-genetic remodeling drives leukemia propagation and reveals actionable vulnerabilities in acute myeloid leukemia.Cell reports. Medicine · 2026Article
- Metabolic Reprogramming of Cancer Stem Cells: Targeting Lipid Flux and Mitochondrial Plasticity to Overcome Therapeutic Resistance.Cancer medicine · 2026Review
- CPT1A through succinylation regulates the CTCF/LINC01503‒91aa feedback loop to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.Clinical and translational medicine · 2026Article
- Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities.The FEBS journal · 2026Review
- RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis.Science advances · 2026Article
- Myeloid differentiation-associated autophagy drives venetoclax resistance in AML.Research square · 2026Article
- Elevated mitochondrial protein import in acute myeloid leukemia increases reliance on mitochondrial protease LONP1.The Journal of clinical investigation · 2026Article
- Mitochondrial metabolism determines chemotherapy sensitivity in colorectal cancer.Nature metabolism · 2026Article
- The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming.Nature aging · 2026Article
- Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies.European journal of haematology · 2026Review
- The KDM-family inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing a ferroptosis-like phenotype.Blood neoplasia · 2026Article
- TIAR-dependent coordination of alternative splicing and lipid peroxidation is required for CML cell resistance to imatinib in the bone marrow stroma.bioRxiv : the preprint server for biology · 2026Article
- Specific FbioRxiv : the preprint server for biology · 2026Article
- Multiomic State-Transitions Reveal Post-Treatment Transcriptome Desynchronization in Acute Myeloid Leukemia.bioRxiv : the preprint server for biology · 2026Article
- Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights.Cancer chemotherapy and pharmacology · 2026Review
514 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
43 authors at 2 institutions in 1 country.
Thomas FargeInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Estelle SalandInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Fabienne de ToniInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Nesrine ArouaInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Mohsen HosseiniInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Robin PerryDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Claudie BoscInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Mayumi SugitaDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Lucille StuaniInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Marine FraisseInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Sarah ScotlandInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Clément LarrueInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Héléna BoutzenInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Virginie FéliuInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Marie-Laure Nicolau-TraversInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Stéphanie Cassant-SourdyInserm, Institut des Maladies Métaboliques et Cardiovasculaires, U1048, Toulouse, France.
Nicolas BroinInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Marion DavidInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Nizar SerhanInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Audrey SarryService d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France. jean-emmanuel.sarry@inserm.fr.
Suzanne TavitianService d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
Tony KaomaProteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, Strassen, Luxembourg.
Laurent VallarProteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, Strassen, Luxembourg.
Jason IacovoniInserm, Institut des Maladies Métaboliques et Cardiovasculaires, U1048, Toulouse, France.
Laetitia K LinaresInserm, Institut de Recherche en Cancérologie de Montpellier, U1194, Montpellier, France.
Camille MontersinoInserm, Centre de Recherche en Cancérologie de Marseille, U1068, Marseille, France.
Rémy CastellanoInserm, Centre de Recherche en Cancérologie de Marseille, U1068, Marseille, France.
Emmanuel GriessingerInserm, Centre Méditerranéen de Médecine Moléculaire, U1065, Nice, France.
Yves ColletteInserm, Centre de Recherche en Cancérologie de Marseille, U1068, Marseille, France.
Olivier DuchampConsortium IMODI "Innovative MODels Initiative against Cancer," France.
Yara BarreiraConsortium IMODI "Innovative MODels Initiative against Cancer," France.
Pierre HirschSorbonne Universités, UPMC Université Paris 06, UMR-S 938, CDR Saint-Antoine, Paris, France.
Tony PalamaUniversité de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France.
Lara GalesUniversité de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France.
François DelhommeauSorbonne Universités, UPMC Université Paris 06, UMR-S 938, CDR Saint-Antoine, Paris, France.
Barbara H Garmy-SusiniInserm, Institut des Maladies Métaboliques et Cardiovasculaires, U1048, Toulouse, France.
Jean-Charles PortaisUniversité de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France.
François VergezInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Mary SelakDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Gwenn Danet-DesnoyersDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Martin CarrollDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Christian RécherInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
Jean-Emmanuel SarryInserm, Cancer Research Center of Toulouse, U1037, Toulouse, France. jean-emmanuel.sarry@inserm.fr.
Institut Paoli-Calmettes · FRUniversité de Montpellier · FR
Funding
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid LeukemiaR01CA198089 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARROLL, MARTIN · 2015 to 2019
$3.3MStem Cells, Differentiation and Therapeutic Resistance in AMLR01CA149566 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARROLL, MARTIN · 2011 to 2015
$3.0MTherapeutic targeting of Src kinase signal transduction pathways in AMLI01BX000918 · VA · PHILADELPHIA VA MEDICAL CENTER · PI CARROLL, MARTIN · 2012 to 2015
–BLRD VA I01 BX000918NCI NIH HHS R01 CA149566NCI NIH HHS R01 CA198089
Abstract
Chemotherapy-resistant human acute myeloid leukemia (AML) cells are thought to be enriched in quiescent immature leukemic stem cells (LSC). To validate this hypothesis
Indexed as
AnimalsCD36 AntigensCell LineageCell Line, TumorCytarabineDrug Resistance, NeoplasmHumansLeukemia, Myeloid, AcuteMiceMitochondriaNeoplastic Stem CellsOxidative PhosphorylationXenograft Model Antitumor AssaysCD36 AntigensCytarabine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.